Neutrophil-Mediated Experimental Metastasis Is Enhanced by VEGFR Inhibition in a Zebrafish Xenograft Model by Lamers, Gerda EM et al.
 
Neutrophil-Mediated Experimental Metastasis Is Enhanced by
VEGFR Inhibition in a Zebrafish Xenograft Model
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation He, Shuning, Gerda E. M. Lamers, Jan-Willem M. Beenakker,
Chao Cui, Veerander P. S. Ghotra, Erik H. J. Danen, Annemarie
H. Meijer, Herman P. Spaink, and B. Ewa Snaar-Jagalska. 2012.
Neutrophil-mediated experimental metastasis is enhanced by
VEGFR inhibition in a zebrafish xenograft model. The Journal
of Pathology 227(4): 431-445.
Published Version doi:10.1002/path.4013
Accessed February 19, 2015 11:53:34 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:10591707
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions




J Pathol 2012; 227: 431–445
Published online in Wiley Online Library
(wileyonlinelibrary.com) DOI: 10.1002/path.4013
Neutrophil-mediated experimental metastasis is enhanced
by VEGFR inhibition in a zebraﬁsh xenograft model
Shuning He,1,4 Gerda EM Lamers,1 Jan-Willem M Beenakker,2 Chao Cui,1 Veerander PS Ghotra,3 Erik HJ Danen,3
Annemarie H Meijer,1 Herman P Spaink1 and B Ewa Snaar-Jagalska1*
1 Institute of Biology, Leiden University, Einsteinweg 55, 2333 CC Leiden, The Netherlands
2 Leiden Institute of Physics, Leiden University, 2300 RA Leiden, The Netherlands
3 Division of Toxicology, Leiden/Amsterdam Centre for Drug Research, Leiden University, 2300 RA, The Netherlands
4 Department of Pediatric Oncology, Dana-Farber Cancer Institute, and Children’s Hospital Boston, Harvard Medical School, Boston, MA 02115,
USA
*Correspondence to: B Ewa Snaar-Jagalska, Institute of Biology, Leiden University, Einsteinweg 55, 2333 CC Leiden, The Netherlands.
e-mail: b.e.snaar-jagalska@biology.leidenuniv.nl
Re-use of this article is permitted in accordance with the Terms and Conditions set out at http://wileyonlinelibrary.com/
onlineopen#OnlineOpen_Terms.
Abstract
Inhibition of VEGF signalling effectively suppresses localized tumour growth but accelerates tumour invasiveness
and micrometastasis by unknown mechanisms. To study the dynamic and reciprocal interactions between tumour
cells and their microenvironment during these processes, we established a xenograft model by injecting tumour
cells into the blood circulation of transparent zebraﬁsh embryos. This reproducibly results in rapid simultaneous
formation of a localized tumour and experimental micrometastasis, allowing time-resolved imaging of both
processes at single-cell resolution within 1 week. The tumour vasculature was initiated de novo by remodelling
of primitive endothelial cells into a functional network. Roles of myeloid cells in critical tumourigenesis
steps such as vascularization and invasion were revealed by genetic and pharmaceutical approaches. We
discovered that the physiological migration of neutrophils controlled tumour invasion by conditioning the
collagen matrix and forming the metastatic niche, as detected by two-photon confocal microscopy and second
harmonic generation. Administration of VEGFR inhibitors blocked tumour vascularization and a localized tumour
growth but enhanced migration of neutrophils, which in turn promoted tumour invasion and formation of
micrometastasis. This demonstrates the in vivo cooperation between VEGF signalling and myeloid cells in
metastasis and provides a new mechanism underlying the recent ﬁndings that VEGFR targeting can promote
tumour invasiveness.
Copyright  2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
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Introduction
Vascular endothelial growth factor (VEGF) is an
essential mediator of vascularization under both
physiological and tumour conditions. Due to the control
function of tumour vascularization in development of
both primary and secondary tumours [1], VEGF sig-
nalling is one of the leading therapeutic targets for
cancer treatment [2]. Unfortunately, clinical results of
anti-angiogenic therapies targeting the VEGF recep-
tor tyrosine kinase (VEGFR) or VEGF have been
more modest than predicted by initial preclinical stud-
ies, and frequently effects on overall patient survival
have been absent or minor [2–6]. Recent preclin-
ical and clinical studies have shown that, despite
the suppression of localized primary tumour growth,
inhibition of VEGF signalling can promote tumour
invasiveness and elicit early-stage micrometastasis
[2,7–12]. Although the underlying mechanism is not
yet clear, the tumour microenvironment, as the primary
target of the anti-angiogenic agents, is thought to play
an important role in the elevated malignancy [3,13,14].
Tumour progression is controlled by dynamic and
reciprocal interactions between malignant tumour cells
and non-malignant cells in their microenvironment
[13,14]. Tumour cells secrete pro-angiogenic factors,
including VEGF, to activate the endothelial cells of
neighbouring blood vessels and trigger angiogenesis to
form tumour neovasculatures [15]. The tumour stromal
cells, including ﬁbroblasts and bone marrow-derived
cells (BMDCs), can secrete pro-angiogenic factors and
control the angiogenic switch [16,17]. The myeloid lin-
eages of BMDCs can be recruited by tumour cells
to enhance their survival and aggressiveness [15]. It
has been shown that CD11b+ Gr1+ myeloid cells,
which include neutrophils, macrophages and myeloid-
derived suppressor cells, promote tumour progres-
sion independent of the adaptive immune system,
Copyright  2012 Pathological Society of Great Britain and Ireland. J Pathol 2012; 227: 431–445
Published by John Wiley & Sons, Ltd. www.pathsoc.org.uk www.thejournalofpathology.com432 SH eet al
and that these cells render tumours refractory to
angiogenic blockade by VEGF antibodies [18]. They
have also been implicated in the formation of the
premetastatic niche [19]. However, as these cells are
usually located in deep tissues and can be function-
ally affected by invasive detection methods, in vivo
kinetic studies of their actual roles in tumour pro-
gression remain challenging. Therefore, non-invasive
visualization of the kinetic interaction between tumour
cells and their microenvironment at high resolution
will largely improve our understanding of basic can-
cer biology and will help to design new therapeutic
strategies.
The zebraﬁsh, Danio rerio, has been an impor-
tant animal model for cancer, immune and stem cell
research over the last decade [20–23]. Many molecular
and cellular components that operate during tumouri-
genesis are conserved between zebraﬁsh and mammals.
A wide range of pharmacologically active compounds
elicit physiological responses in zebraﬁsh embryos
comparable to those in mammalian systems [24], mak-
ing zebraﬁsh ideal for identifying clinically relevant
genes and compounds that regulate tumour progres-
sion. The transparency of zebraﬁsh, in combination
with the availability of various tissue-speciﬁc ﬂuo-
rescent reporter transgenic lines [25,26], allows high
resolution in vivo analysis of tumour progression and
the interactions between tumour cells and the host
microenvironment [27,28]. Several tumour transplan-
tation assays with human and mammalian cells have
been developed to study different aspects of tumour
malignancies in embryo and adult zebraﬁsh, such as
tumour cell migration, proliferation, angiogenesis and
tumour cell extravasation [25,27–31]. However, most
of these assays are limited to one selected step of
tumour development and do not represent the full com-
plexity of tumourigenesis in one model. In addition, for
zebraﬁsh embryonic engraftment models there are no
reports published describing tumour cells extravasation
from the circulation and invasion into the surround-
ing tissue where cells proliferate to form experimental
metastases.
We have established a rapid, reproducible zebraﬁsh
embryonic xenograft model for simultaneous formation
of a localized tumour and experimental micrometas-
tasis by intravascular injection of tumour cells into
the blood circulation of zebraﬁsh embryos. With non-
invasive high-resolution imaging we characterized the
critical steps of tumour progression, including tumour
vascularization and tissue invasion. Using this model,
we found that myeloid cells are involved in these
tumour processes, and especially that neutrophils con-
dition the collagen matrix to facilitate metastatic
niche formation and tumour invasion. Importantly,
we show that VEGFR inhibitors suppress localized
tumour growth but, in contrast, promote tumour inva-
sion and micrometastasis formation by enhancing neu-
trophil migration.
Materials and methods
Zebraﬁsh maintenance, morpholino injection
and pharmacological treatment
Zebraﬁsh and embryos were raised, staged and main-
tained according to standard procedures in compliance
with the local animal welfare regulations. The trans-
genic lines Tg(ﬂi1:GFP) and Tg(mpx:GFP)i114 were
used in this study [25,26]. 0.2 mM N-phenylthiourea
(PTU; Sigma) was applied to prevent pigment for-
mation from 1 day post-fertilization (dpf). For Pu.1
knockdown as previously published, Pu.1 MO (1 mM
for partial knockdown and 2 mM for complete knock-
down [32] was injected into the yolk at the one-cell
stage, as described [33]. For pharmacological inhibi-
tion, the VEGFR tyrosine kinase inhibitors KRN633
(0.1–1.0 µM; Santa Cruz) or Sunitinib (0.1–1.0 µM;
Sigma), beclomethasone (25 µM; Sigma) and β-amino-
proprionitrile (βAPN, 500 µM; Sigma) were applied
directly to the egg water and refreshed every 2 days.
Cell lines
Murine aortic endothelial (MAE) cells and tumouri-
genic FGF2-over-expressing FGF2-T-MAE cells [34]
(provided by M. Presta, University of Brescia, Italy)
and the human breast carcinoma cell line MDA-MB-
231 [35] (provided by P. ten Dijke, Leiden Univer-
sity Medical Centre, The Netherlands) were cultured
as previously described. 4T1 (CRL-2539, ATCC) and
PC3 (CRL-1435, ATCC) cells were cultured in RPMI
1640 supplemented with 10% fetal bovine serum (FBS;
Invitrogen). Stable ﬂuorescent cell lines were generated
using lentiviral vectors expressing dsRed or mCherry
(provided by R. C. Hoeben, Leiden University Medi-
cal Centre, The Netherlands). The virus-infected cells
were used for experiments without FACS sorting and
the ﬂuorescence was stable in vitro for > 10 passages.
Zebraﬁsh ﬁbroblast cell lines ZF4 and PAC2 were cul-
tured as previously described [36].
Embryo preparation and tumour cell implantation
Dechorionized 2dpf zebraﬁsh embryos were anaes-
thetized with 0.003% tricaine (Sigma) and positioned
on a 10 cm Petri dish coated with 1% agarose. Mam-
malian cells were trypsinized into single cell suspen-
sions, resuspended in phosphate-buffered saline (PBS;
Invitrogen), kept at room temperature before implan-
tation and implanted within 3 h. Non-ﬂuorescent cells
were labelled with the ﬂuorescent cell tracker CM-DiI
(Invitrogen) according to the manufacturer’s instruc-
tions. The cell suspension was loaded into borosilicate
glass capillary needles (1 mm o.d. × 0.78 mm i.d.;
Harvard Apparatus) and the injections were performed
using a Pneumatic Pico pump and a manipulator
(WPI). 50–400 cells, manually counted, were injected
at approximately 60 µM above the ventral end of the
duct of Cuvier where it opens into the heart. After
implantation with mammalian cells, zebraﬁsh embryos
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(including non-implanted controls) were maintained at
34
◦C to compromise between the optimal temperature
requirements for ﬁsh and mammalian cells [37]. Up to
600 implantations were manually achieved per h, with
survival rates of > 90% until 6 days post-implantation
(dpi). For pharmacological inhibition, beclomethasone
was applied to the embryos 4 h before implantation
and KRN633, Sunitinib and βAPN were applied 4–6 h
post-implantation. For each cell line or condition, data
are representative of ≥ three independent experiments,
with ≥30 embryos/group. Experiments were discarded
when the survival rate of the control group was < 90%.
Microscopy and analysis
For live imaging, embryos were anaesthetized using
0.016% tricaine (Sigma) and mounted in 0.6% low-
melting agarose. Fixed embryos were imaged in PBST.
Fluorescent image acquisition was performed using a
Leica MZ16FA stereo microscope, a Leica TCS SPE
confocal microscope or a Zeiss LSM exciter on an
Axio Observer confocal microscope. Confocal stacks
were processed for maximum intensity projections
with Zeiss ZEN2009 software or ImageJ software.
Images were adjusted for brightness and contrast using
ImageJ. Overlays were created using Adobe Photoshop
CS4 or ImageJ. 3D reconstructions and movies were
assembled using ImageJ.
Second-harmonic generation and two-photon
microscopy
Second-harmonic generation (SHG) was used to image
the helical structures of collagen ﬁbres, which are
capable of combining two photons into one [38]. The
two-photon microscopy was performed on a Zeiss 710
NLO upright confocal microscope equipped with a
Spectraphysiscs Deep See MP laser. The images were
obtained with an excitation wavelength of 750 nm and
only emitted light with a wavelength in the range
371–467 nm was detected.
Myeloid cell detection
In the Tg(ﬂi1:GFP) line, the neutrophils in ﬁxed
embryos were detected using the Peroxidase/
Myeloperoxidase Leukocyte Kit (Sigma), as described
previously [39]. The embryos were imaged with trans-
mitted light and the black-stained cells were extracted
using the Threshold function of ImageJ and subse-
quently converted into a selected colour for overlay
with ﬂuorescence images. For macrophage detec-
tion, immunohistochemistry for L-plastin was per-
formed after the myeloperoxidase activity assay and the
Mpx−/L-plastin+ cells were counted as macrophages
[31]. The Tg(mpx:GFP)i114 line was used to monitor
neutrophil migration in vivo [26]. Time-lapse imag-
ing (1 min intervals, ≥30 min) was performed using
a Leica stereoﬂuorescence microscope. The migration
tracks were generated by maximum intensity projec-
tions of the time stacks, using ImageJ. For individual
neutrophil tracking, the ﬁrst 20 GFP+ cells from the
posterior end of the tail ﬁn in each embryo, which
exhibited consistent intensity for at least 15 min, were
tracked and analysed using the Manual Tracking plugin
of ImageJ.
Immunohistochemistry
Whole-mount immunohistochemistry was carried out
as described [40]. Primary antibodies and dilutions
were used as follows: L-plastin (rabbit anti-zebraﬁsh,
1:500; provided by A Huttenlocher [31]), ZO-1
(mouse anti-human, 1:300; Invitrogen), phosphohis-
tone H3 (rabbit anti-human, 1:500; Santa Cruz). A
1:200 dilution of the secondary antibodies (Alexa 405
anti-mouse, Alexa 568 anti-mouse or Alexa 568 anti-
rabbit; Invitrogen) was used for detection.
Tail ﬁn wounding
Zebraﬁsh embryos at 2–3 dpf were anaesthetized
using 0.016% tricaine (Sigma) and then wounded on
the ventral side of the tail ﬁn with the tip of a
glass capillary needle, as described [39]. Wounded
embryos were ﬁxed in 4% paraformaldehyde/PBS at
various time points after the wounding and stored in




Tetramethylrhodamine dextran was injected into the
sinus venosus of anaesthetized zebraﬁsh embryos, as
described [41]. Images were acquired within 10 min
after injection.
Statistical analysis
Statistical analysis was performed using Prism 4 soft-
ware (GraphPad), two- or one-tailed unpaired t-tests
with conﬁdence intervals of 90% or 95%: ns, not signif-
icant (p>0.05); ∗0.01 <p<0.05; ∗∗0.0001 <p<
0.01; ∗∗∗p<0.0001.
Results
Intravascular injection of tumour cells into
zebraﬁsh embryos resulted in localized tumour
growth and micrometastasis within 6 days
In order to develop an experimental metastasis model,
as frequently used in mice, we implanted up to 400
ﬂuorescent tumour cells into the blood circulation
of zebraﬁsh embryos at 2 dpf. The tumour cells
haematogenously disseminated in the embryo imme-
diately after injection into the duct of Cuvier; a wide
circulation channel on the embryonic yolk sac con-
necting the heart to the trunk vasculature (Figure 1A,
B). When > 100 tumour cells were injected, the
embryonic circulation was not sufﬁcient to dissemi-
nate the entire bulk of implanted cells, resulting in
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the accumulation of non-disseminated cells close to the
injection site at the duct of Cuvier (Figure 1B). Using a
Tg(Fli:GFP) endothelial reporter transgenic zebraﬁsh
line with ﬂuorescent vasculature [25], we found that
the accumulated tumour cells induced neovascula-
ture formation and developed into a localized tumour
(Figure 1C–E), whereas the disseminated tumour cells
formed micrometastic colonies in the trunk of the ﬁsh
(Figure 1F–H). Localized tumour growth and experi-
mental micrometastases were also induced by several
other types of mouse- or human-originated tumouri-
genic cell lines, but never by non-malignant cell lines
(Table 1). This novel experimental metastasis assay
bypasses the primary tumour stage and intravasation,
but opens the possibility of using this model to screen
for antimetastatic agents in a few days, instead of
weeks in rodent models.
Tumour vascularization is the critical step
for localized tumour growth
Taking advantage of the transparency of zebraﬁsh
embryos, we performed high-resolution confocal imag-
ing to characterize the localized tumour growth. Shortly
after implantation, the non-disseminated tumour cells
accumulated locally in close association with the primi-
tive endothelial cells of the duct of Cuvier (Figure 2A),
which were subsequently remodelled into neovessel-
like structures by the tumour cells (Figure 2B, C).
Subsequently the neovessels connected and gradu-
ally formed an irregular, tortuous, lumenized vascu-
lature network within 2 days (Figure 2D, E). Partial
blood ﬂow was detected in the tumour vasculature by
microangiography from 3dpi (Figure 2F) and circulat-
ing erythrocytes were observed in the lumen after 4dpi
(Figure 2G).
Notably, only in the embryos where such functional
tumour neovasculature had formed did the localized
tumour cells proliferate and form a tumour mass of
> 0.15 mm diameter by 6dpi. Phosphorylation of his-
tone H3 (pH3), a proliferation marker, was signiﬁ-
cantly increased in both ﬂuorescence-positive tumour
cells and in ﬂuorescence-negative stromal cells of the
localized tumour mass after 4dpi (Figure 2H), when
the tumour vasculature started to be functional. These
results indicate that successful tumour vascularization
was the critical step for localized tumour growth in our
model. Importantly, tumour-induced vascularization in
our model is the ﬁrst example of de novo vasculariza-
tion in a zebraﬁsh xenograft system. This phenomenon
is fundamentally different from tumour vascularization
in a previously described angiogenesis assay, which
monitors growth of new vessels from existing vessels
towards the tumour implant [34].
Tumour cell invasion is the critical step
for micrometastasis formation
The occurrence of micrometastasis, independent of
the localized tumour growth, was also characterized
by high-resolution confocal imaging. Micrometastases
Figure 1. Intravascular injection of tumour cells into zebraﬁsh
embryos resulted in localized tumour growth and micrometastasis
within 6 days. (A) Bright-ﬁeld (left) and ﬂuorescence (right) images
showing the injection of tumour cells (red) into the zebraﬁsh
embryonic circulation (green) via the ventral side of the duct of
Cuvier. (B) Dissemination of implanted tumour cells in embryos
injected with ≤100 (top) or > 100 cells. Dissemination was
observed in almost all embryos (124/125) at 3hpi. ∗Injection sites;
arrows, disseminated tumour cells; the caudal hametopoietic tissue
(CHT) is outlined (top). Note that tumour cells also accumulated
close to the injection site in the example of an embryo injected
with > 100 cells (bottom). Scale bar = 1 mm. (C–E) Progression
of tumour formation. Tumour cells accumulated close to the
injection site at 6hpi (C), induced formation of neovasculature at
2dpi (D) and displayed localized tumour growth at 6dpi (E). (F–H)
Formation of micrometastases. Disseminated tumour cells resided
in the tail at 6hpi (F), invaded into the neighbouring tail ﬁn at
2dpi (G) and formed micrometastasis colonies in the ﬁn tissue at
6dpi (H). Images in (A, B) were acquired using a Leica MZ16FA
stereo microscope; those in (C–H) were acquired using a Leica
TCS SPE confocal microscope with a × 20 dry objective. Red in
(A, B, E), tumour cells labelled with the red cell tracker CM-DiI;
red in (C, D, F–H), tumour cells stably expressing dsRed; green
in all, GFP-endothelial cells of the Tg(Fli:GFP) line. DLAV, dorsal
longitudinal anastomotic vessel; ISV, intersegmental vessel; DA,
dorsal aorta; CV, caudal vein. Data are representative images of
> 20 independent, highly reproducible experiments.
originated from tumour cells disseminated haematoge-
nously directly after implantation. Disseminated cells
were arrested in the host vasculature in the ﬁrst
hour (Figure 3A), and extravasation was detected from
12hpi (Figure 3B). Perivascular tumour cells were
observed in multiple foci, including the optic veins,
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Table 1. Intravascular injection of different cell lines into 2dpf zebraﬁsh embryos
Vascularization/localized Tumour invasion/
Cell line Description tumour growth (%) micrometastasis (%) n
FGF-T-MAE MAE cells transformed by FGF2 over-expression 97.0 32.8 67
4T1 Mouse breast cancer 64.7 15.5 142
MDA-MB-231 Human breast cancer 0 47.9 48
PC3 Human prostate cancer 25.0 0 60
MAE Mouse endothelial 0 0 > 100
ZF4/PAC2 Zebraﬁsh ﬁbroblast cell lines 0 0 > 100
For each cell line, data are representative of ≥ three independent experiments (each n > 45). The migratory potential for all tumour cells used in Table 1 was detected
at 6dpi after yolk implantation of 2dpf embryos (data not shown [37]).
Figure 2. Tumour vascularization and localized tumour growth. (A–E) Initiation of tumour-induced neovasculature. Fli: GFP embryos were
imaged from the ventral side to achieve a top view of dsRed-labelled FGF-T-MAE tumour cells, which, after implantation, accumulated
under the primitive endothelial cells of the duct of Cuvier (A; 6hpi, with magniﬁcation in the right panel). At 12hpi, the primitive
endothelial cells in close association with the tumour cells started to change morphology (B). At 18hpi, the primitive endothelial cells were
remodelled into vessel-like structures (C; three connected GFP-endothelial cells). The remodelled endothelial cells were further connected
within the tumour cell mass at 1dpi (D, with magniﬁcation in the right panel). At 2dpi, a partially lumenized vasculature network had
formed within the tumour cell mass (E). (F) Microangiography with tetramethylrhodamine dextran showing partial blood ﬂow in the
tumour vessels at 3dpi (red, indicated by arrows). ∗Some leakage of the tumour vessels was also observed. (G) An expanded tumour mass
of FGF-T-MAE-mCherry cells, supported by a functional vasculature network, at 6 dpi. Right panel shows magniﬁcations of a pectoral ﬁn
vessel (top) and a tumour vessel (bottom). Circulating blood cells within the vessels are indicated by arrows (overlay of transmitted light
and GFP channel). (H) Phosphohistone H3 (pH3, blue) staining of Fli:GFP embryos implanted with FGF-T-MAE-mCherry cells. The pH3+
staining, as a marker of proliferation, was increased in both mCherry+ and mCherry− cell populations after 4dpi, when circulating blood
cells started to be detected in the tumour neovasculature. Data are representative images of > 10 independent, reproducible experiments
(each n > 30). Images in (A–E, H) were acquired using a Zeiss LSM exciter on an Axio Observer confocal microscope with a × 20 dry
objective or a × 63 water objective; those in (F, G) were acquired using a Leica TCS SPE confocal microscope with a × 63 water objective.
Scale bars = 50 µM.
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Figure 3. Tumour cell extravasation, invasion and formation of
micrometastases. (A) DsRed-labelled FGF-T-MAE cells detected at
6 hpi within the intersegmental vessel (ISV, left), the dorsal aorta
(DA, right) and the caudal vein (CV, right). (B) Multiple dsRed-
labelled FGF-T-MAE cells having extravasated from the DLAV (left),
dorsal aorta (right) and caudal vein (right) at 1 dpi. Only one cell
remainedinthedorsalaorta(indicatedby ∗).(C) Tworepresentative
examples of FGF-T-MAE tumour cell invasion from the posterior
end of the caudal haematopoietic tissue into the tail ﬁn at 1 dpi.
(D) A cluster of > 35 MDA-MB-231 cells (red, CM-DiI labelled)
resident in the tail ﬁn at 6dpi (left, ﬂuorescence; right, transmitted
light).(E) Phosphohistone-H3-positive(showninblue)proliferation
of tumour cells after micrometastasis formation: (left) tail ﬁn
without micrometastasis; (right) tail ﬁn with micrometastasis.
Data are representative images of > 10 independent, reproducible
experiments (each n > 30) all using Tg(ﬂi–GFP) zebraﬁsh embryos.
Images in (A–C) were acquired using a Zeiss LSM exciter on an
Axio Observer confocal microscope with a × 63 water objective;
(D, E) were acquired using a Leica TCS SPE confocal microscope
with a × 20 dry objective. Scale bars = 50 µM.
the inter-segmental vessels, the dorsal aorta and the
caudal vein (Figure 3B). Most of the perivascular ﬂuo-
rescent signals disappeared before 4dpi, indicating the
regression of extravasated cells without initiating tis-
sue invasion and proliferation. However, exclusively
at the posterior ventral end of the caudal haematopoi-
etic tissue (CHT, as indicated in Figure 1B) in the tail,
perivascular tumour cells were able to invade into the
neighbouring tail ﬁn within 1dpi (Figure 3C).
The spatially speciﬁc invasion site was validated
by other tested tumour cell lines (Figures 1F, H, 3E,
Table 1). Such tumour cell invasion was the critical
step for micrometastasis formation, as pH3-positive
proliferating cells were only detected after successful
invasion and formation of 3–50 cell micrometastases
in the tail ﬁn (Figure 3D). No angiogenesis towards the
micrometastases was observed before the termination
of experiments at 6dpi. Experiments were terminated at
this stage to comply with European animal regulations.
When the embryos were maintained under hypoxic
conditions after implantation, there was no signiﬁcant
increase of invasion compared with normoxic condi-
tions (unpublished data). Taken together, dissemination
and extravasation events were not site-speciﬁc, while
tumour cell invasion and formation of micrometastic
colonies occurred only at posterior end of the cau-
dal haematopoietic tissue (equivalent to human bone
marrow).
Myeloid cells are involved in tumour vascularization
and invasion
Leukocytes are known to contribute to different steps of
tumour progression, including the formation of tumour
vasculature and metastasis [14,16–18]. In zebraﬁsh
embryos, the caudal haematopoietic tissue (CHT) is
known as a transient site of haematopoiesis and leuko-
cyte differentiation [29]. Our observation that tumour
cell invasion occurred at the posterior end of the CHT
suggested the involvement of leukocytes in tumour pro-
gression. In the ﬁrst few days of zebraﬁsh development,
macrophages and neutrophils are the only populations
of functional leukocytes in the embryos [30]. Using
a combination of myeloid lineage markers (Mpx+
for neutrophils and Mpx−/L-plastin+ for macrophages
[31]), we detected that FGF-T-MAE tumour cells were
accompanied by cells of the myeloid lineages, both
at the localized tumour growth site near the site of
implantation and at the invasion site at the posterior
end of the CHT (Figure 4).
To investigate the role of myeloid cells in tumour
progression, we used morpholino oligonucleotides to
knock down the transcription factor Pu.1, which con-
trols the development and differentiation of myeloid
cells in zebraﬁsh embryos [32]. As previously shown,
Pu.1 knockdown is most effective in suppressing
macrophage differentiation, while neutrophil differen-
tiation can be suppressed only under maximal knock-
down conditions [42]. In agreement, in our experiments
macrophages were depleted in zebraﬁsh embryos up
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Figure 4. Myeloid cells associated with tumour cells at the
localized tumour and micrometastasis sites. (A) Neutrophils [green;
Tg(mpx:GFP)i114] associated with FGF-T-MAE tumour cells (red)
at the localized tumour growth site. (B) Neutrophils (blue; Mpx+
histochemicalstaining)associatedwiththetumourcells(red)atthe
micrometastasis site. (C, D) Macrophages (blue; Mpx−/L-plastin+)
associated with the tumour cells (red) at the localized tumour
(C) and micrometastasis (D) sites. Data are representative images
of > 10 independent, reproducible experiments (each n > 30).
Image in (A) was acquired using a Leica MZ16FA stereo microscope
(bright-ﬁeld/ﬂuorescence overlay image); those in (B–D) were
acquired using a Leica TCS SPE confocal microscope with a × 20
dry objective.
to 3dpf by a partial knockdown of Pu.1 (1 mM mor-
pholino; Figure 5A), while neutrophils were depleted
by the complete knockdown of Pu.1 (2 mM mor-
pholino; Figure 5A). Using these different doses of
Pu.1 morpholino, we found that the formation of
tumour neovasculature, but not the physiological vas-
culature, was impaired under both partial and complete
knockdown conditions of Pu.1 (Figure 5B, C), sug-
gesting a major role of macrophages in the tumour
vascularization. In contrast, tumour cell invasion at the
posterior end of the CHT was only suppressed by com-
plete knockdown of Pu.1, not by partial knockdown
(Figure 5D, E), indicating that neutrophils play a pre-
dominant role in tumour cell invasion and micrometas-
tasis. Taken together, myeloid cells are involved in the
processes of both tumour vascularization and invasion,
the critical steps towards localized tumour growth and
micrometastasis.
A previous study of zebraﬁsh myeloid cells sens-
ing of HRASG12V-transformed cells suggested homolo-
gies between the myeloid cell responses towards
transformed cells and wound-induced inﬂammation
[27]. Therefore, we investigated the inﬂuence of
wound-induced inﬂammation on tumour progression
in our model. When the embryos were wounded at
the tail-ﬁn, we observed that tumour cell invasion
was largely suppressed or abolished (Figure 5F). This
suppression of tumour invasion was probably caused
by inﬂammation-enhanced myeloid cell phagocyto-
sis, as the majority of implanted tumour cells were
phagocytosed by L-plastin+ myeloid cells (Figure 5G).
This result suggests that, in the absence of wounding,
myeloid cells contribute to tumour vascularization and
invasion in an inﬂammation-independent physiological
manner.
Physiological neutrophil migration conditions
the collagen matrix for tumour cell invasion
To further investigate the involvement of neutrophils
in tumour cell invasion, the physiological migration
of neutrophils in 3dpf embryos was analysed using the
Tg(mpx:GFP)i114 neutrophil-speciﬁc zebraﬁsh reporter
line [26]. Time-lapse and trajectories analysis showed
that neutrophils randomly transmigrated between the
caudal haematopoietic tissue and the tail ﬁn (termed
‘CHT–TF transmigration’), as a part of their phys-
iological unrestricted random migration. This non-
directional motion of neutrophils occurred selectively
at the posterior end of the CHT, where the perivas-
cular tumour cells invaded into the tail ﬁn (Figure 6A,
B). The spatial preference for this location of CHT–TF
transmigration was not altered by tumour cell implanta-
tion (Figure 6B, C) or by wound-induced inﬂammation
(unpublished data and [43,44]), suggesting that it is the
normal physiological property of neutrophil migration
in zebraﬁsh embryos.
To further decipher the impact of neutrophil CHT–
TF transmigration on the spatially co-localized tumour
cell invasion process, two-photon excited confocal
microscopy and SHG was performed to visualize the
extracellular ﬁbrillar collagen matrix upon neutrophil
migration [38]. Migrating neutrophils created transient
tracks of deformed collagen matrix, as detected by the
loss of SHG signal (Figure 6D), which was previously
reported to be sufﬁcient to support tumour cell invasion
in mice models [45]. As a consequence of the localized
neutrophil CHT–TF transmigration, the deformation of
the collagen matrix was largely enhanced at the pos-
terior end of the CHT, where the perivascular tumour
cells invaded into the tail ﬁn (Figure 6E). Furthermore,
we observed that the tumour cells invaded into the
tail ﬁn at the exact site of local collagen deformation
(Figure 6F). Thus, the observed tumour cell invasion
was promoted by physiological neutrophil migration
(the CHT–TF transmigration), which conditions the
extracellular collagen matrix.
Pharmacological approaches were taken to conﬁrm
the functional involvement of neutrophil migration
in tumour cell invasion. A prototype glucocorticoid
receptor agonist, beclomethasone, previously shown
to inhibit neutrophil migration [46], did not cause
alteration of the ﬁbrillar collagen matrix in zebraﬁsh
embryos (data not shown). We detected an inhibi-
tion of the normal physiological neutrophil migration
and of neutrophil chemotaxis directed by wounding-
induced inﬂammation [39] at 4 h after administration
of 25 µM beclomethasone (Figure 7A, B, D). Tumour
cell invasion and micrometastasis was also reduced
in embryos incubated in 25 µM beclomethasone 4 h
before implantation (Figure 7C). In addition, we found
that the lysyl oxidase inhibitor β-aminoproprionitrile
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Figure 5. Myeloid cells contribute to tumour vascularization and invasion. (A) Lineage-speciﬁc depletion of macrophages and neutrophils
by dose-dependent morpholino-mediated knockdown of Pu.1. Neutrophils are shown in black (Mpx+ histochemical staining) and
macrophages are shown in red (Mpx−/L-plastin+). In each embryo, the macrophages in the region 0.5 mm from the posterior end of the
tail ﬁn and the neutrophils in the region 1 mm from the posterior end of the tail ﬁn were quantiﬁed, which are sufﬁcient to represent
each linage distribution in the entire embryo. (B, C) Suppression of FGF-T-MAE tumour vascularization under partial (1 mM) or complete
(2 mM) knockdown of Pu.1 was signiﬁcant (Wilcoxon test, p < 0.01). Representative embryos with tumour vascularization in the control
and Pu.1 knockdown conditions at 3dpi are shown in (B) and quantiﬁcation of tumour vascularization at 1dpi are shown in (C). Data are
representative of > three independent experiments (each n ≥ 27). (D, E) Suppression of FGF-T-MAE tumour cell invasion at the posterior
end of the CHT under complete knockdown of Pu.1 was signiﬁcant (Wilcoxon test, p < 0.01). Representative control and Pu.1 knockdown
embryos at 1dpi (D) and embryos scored for tumour cell invasion at 1dpi (E). Data are representative of > three independent experiments
(each n > 70). (F) Suppression of tumour cell invasion by wound inﬂammation in the tail ﬁn at 1dpi was signiﬁcant (Wilcoxon test,
p < 0.001). A wound in the tail ﬁn was made mechanically (as in Figure 7D) just after implantation of tumour cells at 2dpf. Data are
representative of three independent experiments (each n ≥ 60). (G) Phagocytosis of tumour cells (indicated by arrows) around the invasion
site by myeloid cells in embryos in which the tail ﬁn was wounded (positioned by ‘W’); tumour cells are shown in red and myeloid cells
were stained for L-plastin (blue). Images are representative of > three independent experiments (each n > 30). Images in (A, B, D) were
acquired using a Leica TCS SPE confocal microscope with a × 20 dry objective; those in (G) were acquired using a Zeiss LSM exciter on an
Axio Observer confocal microscope with a × 20 dry objective.
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Figure 6. Physiological migration of neutrophils between the caudal haematopoietic tissue and the tail ﬁn at the tumour invasion site
conditions the collagen matrix for tumour cell invasion. (A) Migration tracks of GFP+ neutrophils in the tail of a Tg(mpx:GFP)i114 embryo
(30 min time-lapse with 1 min intervals). GFP+ neutrophils only transmigrated between the caudal haematopoietic tissue (CHT) and the
tail ﬁn (TF) at the site where tumour cells invaded into the tail ﬁn. The CHT–TF transmigration area is indicated in the left panel, which
shows invasion of the tail ﬁn by a dsRed-labelled FGF-T-MAE cell in a 3dpf Tg(ﬂi:GFP) embryo (top, bright-ﬁeld; bottom, ﬂuorescence
image). Manual tracking of 30 min migration patterns (right panel) of GFP+ neutrophils in the highlighted region of the tail of a 3dpf
Tg(mpx:GFP)i114 embryo (middle panel) showed that the transmigrating neutrophils (red, yellow and blue tracks) migrated as randomly
as neighbouring neutrophils in the tail (orange and light blue tracks) or already inside the ﬁn tissue (purple track). (B) Quantiﬁcation of
neutrophil transmigration into the tail ﬁn. Time-lapse recordings were made of 3dpf Tg(mpx:GFP)i114 embryos with (n = 5) or without
(n = 14) implanted FGF-T-MAE tumour cells, and the number of times that GFP+ neutrophils crossed the CHT–TF boundary was counted
in two areas of the tail, the tumour invasion site (I) and the non-invasion site (NI), as indicated in (A). The CHT–TF transmigration of
neutrophils selectively occurred at the same site as tumour invasion. This spatial preference was not inﬂuenced by implantation. Data
are representative images of > three independent, reproducible experiments (> 30 embryos examined in total). (C) Recording (2 h) of
neutrophil (green) migration in Tg(mpx:GFP)i114 embryos after implantation of FGF-T-MAE tumour cells (red). The selective neutrophil
CHT–TF transmigration site, overlapping with the tumour invasion site, is outlined. (D–F) Second-harmonic generation (SHG) analysis
of the ﬁbrillar collagen matrix around the CHT–TF transmigration site. Images show an overlay of SHG signal (grey) with ﬂuorescence
of GFP+ neutrophils [Tg(mpx:GFP)i114] and red CM-DiI-labelled FGF-T-MAE tumour cells. (D) Example of a track (indicated by arrow)
of deformed collagen matrix in the tail ﬁn created by a migrating neutrophil. (E) Comparison of a region in the tail ﬁn with no recent
neutrophil migration events (left) and a region showing SHG-negative tracks (indicated with arrows) generated by migrating neutrophils
(right). (F) Invasion of tumour cells in an SHG-negative site in the tail ﬁn: (top) overlap of SHG and green ﬂuorescence signal of neutrophils;
(bottom) red ﬂuorescence signal of tumour cells. The local loss of SHG signal is indicated by the arrow in the top image. Images in (A, C)
were acquired using a Leica MZ16FA stereo microscope; those in (D, E) were acquired using a Zeiss 710 NLO upright two-photon confocal
microscope with a × 20 water objective. Scale bars = 50 µM.
(βAPN) largely reduced ﬁbrillar collagen (unpub-
lished data) and enhanced the CHT–TF transmigra-
tion of neutrophils, leading to a signiﬁcant increase
of tumour cell invasion and subsequent formation
of micrometastases (Figure 7A–C). Notably, βAPN
inhibited neutrophil chemotaxis induced by inﬂamma-
tion (Figure 7D), indicating that the increase of tumour
cell invasion in βAPN-treated embryos was correlated
with enhanced non-pathological neutrophil migration,
but not with inﬂammation. Neither beclomethasone
nor βAPN had any signiﬁcant effect on macrophage
chemotaxis (Figure 7D) and tumour vascularization
(Figure 9I). Taken together, these results reveal that
only non-pathological neutrophil migration and the
spatially restricted CHT–TF transmigration modify
the extracellular matrix and have a major impact
on tumour cell invasion and micrometastasis in this
model.
VEGFR inhibitors suppress tumour vascularization,
but promote tumour cell invasion by enhancing
neutrophil migration
Tumour vascularization is an important process in
tumour progression. In our model, the localized tumour
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Figure 7. Tumour cell invasion is controlled by non-pathological neutrophil migration. (A) The random non-pathological migration of
neutrophils was suppressed by beclomethasone (25 µM) and promoted by βAPN (500 µM). Migration tracks (••µ m) of neutrophils in 3dpf
Tg(mpx:GFP)i114 embryos were recorded over 10 min intervals (n ≥ 5 embryos/treatment group; n > •• total neutrophil tracks/treatment
group). (B) The CHT–TF transmigration of neutrophils was suppressed by beclomethasone and promoted by βAPN. Transmigration events in
non-invasion (NI) and invasion (I) areas of the tail ﬁn were quantiﬁed as in Figure 6B. (C) Tumour cell invasion at the posterior end of the
CHT was signiﬁcantly suppressed by beclomethasone (Wilcoxon test, p < 0.01) and promoted by βAPN (p < 0.01). Embryos were scored
for tumour cell invasion at 1dpi. Data are representive of > ﬁve independent experiments (each n > 60). (D) Wounding-induced myeloid
cell chemotaxis was affected by different pharmacological treatments. 3dpf embryos were wounded in the tail ﬁn, as indicated by arrows in
representative images of embryos from different treatment groups (no treatment; 25 µM beclomethasone; 500 µM βAPN; 1 µM KRN633)
at 2 h post-wounding (hpw). Embryos were ﬁxed at different time points over a course of 12hpw and stained for neutrophils (Mpx+,
histochemical staining) and macrophages (Mpx−/L-plastin+). Quantiﬁcation of neutrophil and macrophage numbers was performed on
n ≥ 8 embryos/time point for each treatment group. Images were acquired using a Leica TCS SPE confocal microscope with a × 20 dry
objective. The macrophages/neutrophils in the region outlined were quantiﬁed to measure the myeloid cell chemotaxis towards the wound.
Scale bars = 100 µM.
growth was determined by successful vascularization
(Figure 2). Administration of the VEGFR inhibitors
KRN633 or Sunitinib signiﬁcantly inhibited tumour-
induced neovasculature formation, in a dose-dependent
manner (Figure 8A). Such inhibition of tumour vascu-
larization resulted in signiﬁcant suppression of local-
ized tumour growth (Figure 8B). However, we noticed
that tumour cell invasion at the site of CHT–TF trans-
migration was strongly promoted in embryos treated
with the VEGFR inhibitors (Figure 8C). This observa-
tion supports the recent ﬁndings that anti-angiogenic
therapies based on inhibition of VEGF signalling
promote tumour cell invasion and metastasis in mouse
models and in the clinic [7,8,16,47]. It is unlikely
that such enhanced aggressiveness was caused by an
effect on blood vessel integrity in our model, as no
blood vessel leakage in these embryos was detected
by microangiography using tetramethylrhodamine dex-
tran (Figure 8D). Furthermore, immunohistochemistry
with an antibody against the tight junction protein
ZO-1 showed that endothelial cell–cell junctions
remained normal after VEGFR inhibition (Figure 8E).
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Figure 8. VEGFR inhibitors suppress tumour vascularization but promote tumour cell invasion. (A) Tumour vascularization was signiﬁcantly
suppressed by VEGFR inhibitors KRN633 or Sunitinib at both concentrations (Wilcoxon test, p < 0.01). The results were scored at 1dpi
as the percentage of Tg(ﬂi:GFP) embryos showing no (white), minor (grey) and extensive (black) neovasculature formation towards the
FGF-T-MAE tumour cell mass. Representative images of each class are shown. Data are representative of > three independent experiments
(each n > 30). (B) Expansion of the localized tumour mass was inhibited by 0.1 µM VEGFR inhibitor KRN633 or Sunitinib. Images are
representative of > ﬁve independent experiments (each n > 30). (C) Tumour cell invasion at the posterior end of the CHT was signiﬁcantly
enhanced by VEGFR inhibitor KRN633 (Wilcoxon test, p < 0.01 for 0.5 µM). The results were scored at 1dpi, as the percentage of embryos
showing phenotypes of no invasion (white), 1 cell invasion (grey) and > 1 cell invasion (black). Representative images of each class
are shown. Data are representative of ≥10 independent experiments (each n > 30). (D) Microangiography using tetramethylrhodamine
dextran. No leakage was detected at 24 h after administration of 0.1 µM VEGFR inhibitor KRN633 or Sunitinib. Data are representive of
three independent experiments (each n > 3). (E) Immunohistochemistry against the tight junction protein ZO-1. Normal junctions were
detected between endothelial cells at the posterior end of the CHT at 24 h after administration of 0.1 µM VEGFR inhibitor KRN633 or
Sunitinib. Data are representative of three independent experiments (each n > 5). Scale bars = 25 µM. Images were acquired using a
Leica TCS SPE confocal microscope with a × 20 dry objective (A–D) or a × 63 water objective (E).
We then investigated the contribution of myeloid
cells to the tumour cell invasion and micrometasta-
sis promoted by VEGFR inhibition. We found that
VEGFR inhibition led to a reduction of macrophage
numbers, altered the typical elongated macrophage
shape into a rounded morphology and suppressed
the migratory activity of macrophages (Figures 7D,
9A–C). In contrast, the number of neutrophils was
not reduced by VEGFR inhibition (Figure 9D). Fur-
thermore, the random migration and CHT–TF trans-
migration of neutrophils were enhanced upon VEGFR
inhibition, as shown in live recordings (Figure 9E–G).
These results suggest that VEGFR inhibition enhanced
neutrophil migration, which in turn promoted tumour
cell invasion. To test this hypothesis, beclomethasone
was administered to achieve a pharmacological restora-
tion of neutrophil migration upon VEGFR inhibition
(Figure 9G). Subsequently, the tumour cell invasion
promoted by VEGFR inhibition was also restored to the
normal level (Figure 9H). These results conﬁrm that
the VEGFR inhibitors promoted tumour cell invasion
and micrometastasis by the enhancement of neutrophil
migration.
Discussion
The recent discoveries in mice models and clinical
studies showed that anti-angiogenic therapies by tar-
geting the VEGF signalling inhibited primary tumour
growth but promoted tumour invasion and metasta-
sis. Unfortunately, the mechanism of this very relevant
clinical problem is still elusive. Answering this ques-
tion requires live imaging of tumour-microenvironment
interactions at the cellular level—a process severely
limited in current animal models.
Using a novel zebraﬁsh xenograft model that allows
simultaneous single-cell resolution monitoring of
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Figure 9. VEGFR inhibitors promoted tumour cell invasion via enhancement of physiological neutrophil migration. (A–C) Suppression of
macrophages by VEGFR inhibition. 2dpf Tg(ﬂi:GFP) embryos were untreated or treated with 1 µM KRN633 and subsequently stained
for neutrophils (Mpx+, histochemical staining, shown in blue) and macrophages (Mpx−/L-plastin+, shown in red). Myeloid cells in the
tail of representative embryos were quantiﬁed in a 0.5 mm region from the tip of the tail ﬁn. Representative embryos were imaged
at the last 0.5 mm from the tip of the tail ﬁn and counted for myeloid cells. Notably, the elongated morphology of macrophages
was altered to a less migratory phenotype (rounded morphology) after 6 h of treatment (A) and the number of macrophages in this
region was irreversibly reduced after 12 h (B). 24 h administration of KRN633 caused reduction of macrophages in a dose-dependent
manner (C). Images were acquired using a Leica TCS SPE confocal microscope with a × 20 dry objective. Data are representative of
three independent experiments. (D) KRN633 did not reduce neutrophil numbers after 24 h administration. (E) Administration of 0.1 µM
VEGFR inhibitor KRN633 or Sunitinib resulted in elongated neutrophil [Tg(mpx:GFP)i114] migration tracks over a 30 min time frame. The
time-lapse series were acquired using a Leica MZ16FA stereo microscope. (F) The CHT–TF transmigration of neutrophils was promoted
by 0.1 µM KRN633 (n = 5). Transmigration events in non-invasion (NI) and invasion (I) areas of the tail ﬁn were quantiﬁed as in
Figure 6B. (G) The random non-pathological migration of neutrophils was promoted by 0.1 µM KRN633. KRN633-promoted migration was
suppressed by co-administration of 25 µM beclomethasone. Migration tracks (µ m) of neutrophils in 3dpf Tg(mpx:GFP)i114 embryos were
recorded over 10 min intervals. Data are representative of two independent experiments (n > 5 embryos/treatment group; n > 20 total
neutrophil tracks/embryo). (H) Tumour cell invasion promoted by 0.1 µM KRN633 was signiﬁcantly suppressed by 25 µM beclomethasone
(Wilcoxon test, p < 0.01). Tumour cell invasion was quantiﬁed as in Figure 8C. Data are representative for three independent experiments
(each n > 60). (I) Tumour vascularization was signiﬁcantly suppressed by 0.1 µM KRN633 (Wilcoxon test, p < 0.01) but not by 25 µM
beclomethasone or 500 µM βAPN. Embryos were scored for vasculogenesis at 1dpi, as in Figure 5C. Data are representative of > three
independent experiments (each n > 30).
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multi-step tumourigenesis in vivo, including tumour
vascularization, localized tumour growth, tumour inva-
sion and micrometastasis formation, we discovered a
new mechanism of the metastatic niche formation. In
addition to the published roles of macrophages in this
process [14], we found that physiological migration
of neutrophils controlled tumour invasion by condi-
tioning the collagen matrix to facilitate the metastatic
niche. Importantly, we show that VEGFR inhibitors
suppress localized tumour growth but, in contrast, pro-
mote tumour invasion and micrometastasis formation
by enhancing neutrophil migration.
Recently, the zebraﬁsh myeloid cell population has
been studied in detail and similarities with the human
myeloid cell functions and embryonic differentiation
have been demonstrated [48,49]. Further evidence that
the zebraﬁsh holds much potential for translational
studies in cancer has been published [50,51]. Recently
it has been reported that expression of WHIM trun-
cation mutations of CXCR4 in zebraﬁsh neutrophils
induces neutrophil retention in the caudal haematopoi-
etic tissue, which represents a mechanism of human
immunological WHIM disorder. WHIM zebraﬁsh are
neutropenic, and WHIM neutrophils show impaired
recruitment to tissue inﬂammation sites, recapitulating
the human disease. These ﬁndings support the potential
of zebraﬁsh to model primary immune disorders and
underscore the translational relevance of zebraﬁsh neu-
trophils transmigration in understanding disease patho-
genesis [52,53].
The involvement of myeloid cells in critical tumouri-
genesis, steps such as vascularization and invasion,
was revealed by both genetic and pharmacological
approaches. We demonstrated that myeloid cells, par-
ticularly macrophages, are essential for tumour vascu-
larization. Importantly, we also obtained evidence that
the micrometastasis site was determined by the phys-
iological migration of neutrophils. Our results show
that yet undeﬁned environmental cues favour neu-
trophil transmigration at the posterior end of the caudal
haematopoietic tissue, which remodels the ﬁbrillar col-
lagen matrix and in turn conditions the premetastatic
niche for tumour cells to invade into the tail ﬁn. These
ﬁndings support the ‘seed and soil’ hypothesis, that
tumour metastasis is controlled by both the tumouri-
genic property of disseminated cells and their microen-
vironment [54].
It is known that tumour-inﬁltrating immune cells can
have both tumour-promoting and tumour-antagonizing
roles [1]. In our model, the myeloid cells promote
tumour progression under the physiological wound-free
condition (Figure 5C, E), whereas immune-mediated
destruction of tumour cells was hyper-activated by
wound-induced inﬂammation (Figure 5F, G). These
results indicate that environmental factors have an
impact on the balance between the conﬂicting immune
cell responses to tumour cells. Interestingly, we found
that the lysyl oxidase inhibitor βAPN accelerates phys-
iological neutrophil migration but decelerates patho-
logical neutrophil chemotaxis, suggesting that different
molecular mechanisms are involved in different modes
of myeloid cell migration.
Our data support the recent notion that inhibi-
tion of VEGF signalling may have opposite effects
on localized tumour growth and on metastasis. It
has been suggested that hypoxia-resistant cells may
escape from a starving primary tumour treated with
VEGFR inhibitors and then result in elevated malig-
nancy [2,8,12,47]. In our model, micrometastasis origi-
nates from tumour cells disseminated haematogenously
directly after implantation, and therefore hypoxia is
unlikely to be the mediator of enhanced tumour inva-
siveness upon VEGFR inhibition.
Our data provide evidence that the physiological
migration of neutrophils is elevated upon inhibition
of VEGF signalling, which in turn promotes tumour
invasion. This is the ﬁrst demonstration, to our knowl-
edge, of the in vivo cooperativeness between VEGF
signalling and neutrophils in metastasis. In addition,
we observed that macrophages were suppressed by
the VEGFR inhibitors, which may indicate an indi-
rect involvement of macrophages in this process. The
remaining question is, what are the targets of the
VEGFR inhibitors in the neutrophils that cause them
to enhance their migration? The VEGFR inhibitors
used in this study are sufﬁciently different in struc-
ture to ensure that the observations were not due to
an off-target effect. However, we can not be certain
that observed phenotypes are restricted to targeting
of VEGF receptors, since sunitinib works also on
PDGFR family members and affects pericyte cover-
age of endothelium, promoting extravasation of tumour
cells and the formation of micrometastasis [55]. It is
unlikely that the enhanced aggressiveness was caused
by an effect on blood vessel integrity in our model,
as no blood vessel leakage in these embryos was
detected by microangiography using tetramethylrho-
damine dextran. Unfortunately, pericytes have not yet
been described in zebraﬁsh and thus we were unable
to look at them directly.
Our ﬁndings implicate myeloid cells as critical
mediators of tumour invasiveness elicited by VEGFR
inhibitors, independent of inﬂammation and the adap-
tive immune system. It provides a new mechanism
underlying the recent clinical observations of anti-
VEGF therapies promoting tumour invasiveness. We
propose that dual targeting of angiogenesis and myeloid
cells can be beneﬁcial in future treatments. Of course,
it will only be relevant for medical studies if the neu-
trophil transmigration is not restricted to this model.
Currently the role of macrophages in intra- and extrava-
sation of cancer cells is well established [14]. The
role of neutrophils is less studied; however, tumour-
associated neutrophils (TANs) were recently described
and an increased level of neutrophils in cancer patients
was shown to correlate with poor prognosis [56].
For example, a quantiﬁcation of TANs in patients
with renal cell carcinoma revealed that the pres-
ence of neutrophils correlated with increased mor-
tality [56]. In addition, increased levels of TANs
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in the bronchioalveolar space of patients with bron-
chioalveolar carcinoma were signiﬁcantly associated
with poor outcomes [57]. In order to dissect the func-
tion of myeloid cells in human cancers, live imaging
of tumour–microenvironment interactions at the cel-
lular level is required, a process severely limited in
current mammalian models. This limitation strongly
supports the relevance of the zebraﬁsh model to unravel
the molecular mechanisms of how tumour-associated
neutrophils mediate metastasis in zebraﬁsh and mam-
malian models. Furthermore, our zebraﬁsh xenotran-
plantation system provides a new, inexpensive animal
model for rapid preclinical screening of new potential
therapies, for example directed at the VEGF signalling
pathway, at various stages of tumour progression and
metastasis spread in real time in an in vivo model. In
conclusion, we exploited this model here to demon-
strate that neutrophil migration affects metastasis and
that this is enhanced by VEGFR inhibitors.
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